Novo Nordisk

<%= message.delivery.preHeader %>

Nikola looks thoughtfully into the distance holding his camera, his treatment concerns animated around him.

^aBased on a real-world study with 472 people with Hemophilia. Analysis is limited to ABRs in medical records and PROs from the survey and may be limited by medical record discrepancies, recall bias, and potential reporting bias for bleeds.²

DESPITE ADVANCEMENTS IN THERAPY

In a real-world study in Israel of 70 patients with severe hemophilia A³

ON FVIII MIMETIC EXPERIENCED ≥1 SPONTANEOUS BLEED DURING 18 MONTHS OF FOLLOW UP^3,b

In a real-world study with 62 physician responses²

ON SHL AND EHL PROPHYLAXIS EXPERIENCED ≥1 BLEED IN A YEAR, RESPECTIVELY^2,c,d

^cAccording to physicians reporting patients ABR data from medical records among a subset of patients who had bleed data for ≥ 1 year. The study is limited to patients seeking hemophilia care, with potential bias toward those with severe illness or higher healthcare interaction. Additionally, the cross-sectional design may limit changes over time.²

^bA real-world study of 70 patients treated at the Israeli National Hemophilia Center with severe hemophilia A receiving FVIII mimetic therapy for at least 18 months. Patients were evaluated for bleeding episodes.³

^dThe objective of this study was to use the Adelphi Real World (ARW) hemophilia Disease Specific Programme (DSP)™ to gain insights into the real-world characteristics and unmet needs of patients with hemophilia A and B within the current treatment landscape in the United States. From July 2023 to February 2024, 62 physicians who treat and manage patients with hemophilia were identified by ARW through local fieldwork partners. Both the recruited physicians and their patients subsequently completed the survey, which included data from 423 patients (348 with hemophilia A and 75 with hemophilia B). The comprehensive observational survey utilized online physician surveys and self-completion questionnaires for patients and caregivers, employing validated instruments such as EQ-5D-5L, WPAI, Haemo-QoL, and joint health assessment tools (eg, FISH, HJHS).²

UNCOVER ANY TRADE-OFFS YOUR PATIENTS MAY BE MAKING

Dig deeper now

STAY UP TO DATE WITH THE LATEST INFORMATION

Get more updates and communications on hemophilia A from Novo Nordisk as they become available.

ABR=annualized bleeding rate; EHL=extended half-life; FVIII=Factor VIII; FVIIIa=activated Factor VIII; SHL=standard half-life.

References:

1.	Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition [published correction appears in Haemophilia. 2021;27(4):699]. Haemophilia. 2020;26(suppl 6):1-158.
2.	Data on file. Novo Nordisk Inc; Plainsboro, NJ.
3.	Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab. J Clin Med. 2021;10(19):4303.

Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.